(AGL) agilon health - Ratings and Ratios
Outpatient, Post-Acute, Care, Management
AGL EPS (Earnings per Share)
AGL Revenue
Description: AGL agilon health August 18, 2025
Agilon Health Inc (NYSE:AGL) is a healthcare services company listed on the New York Stock Exchange. As a player in the US healthcare industry, the companys performance is influenced by factors such as healthcare reform, reimbursement rates, and patient demographics.
The stock has experienced significant volatility, with a 52-week high of $5.68 and a low of $0.86, indicating a potential risk for investors. The current price is $1.11, substantially lower than its moving averages (SMA20: $1.52, SMA50: $1.95, SMA200: $2.82), suggesting a bearish trend.
From a fundamental analysis perspective, Agilon Healths market capitalization stands at $369.46 million, with a forward Price-to-Earnings ratio of 178.57, indicating high expectations for future earnings growth. However, the companys current Return on Equity (RoE) is -64.59%, raising concerns about its profitability.
Key economic drivers for Agilon Health include the growing demand for healthcare services, particularly among the aging population, and the companys ability to manage costs and navigate complex reimbursement structures. To evaluate the companys performance, investors should monitor KPIs such as revenue growth, patient enrollment numbers, and medical cost ratio.
A critical analysis of Agilon Healths quarterly tax provision is essential to understanding the companys tax obligations and potential impact on its bottom line. A thorough examination of the tax provision can provide insights into the companys tax strategy and potential risks associated with tax law changes or audits.
AGL Stock Overview
| Market Cap in USD | 330m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2021-04-15 |
AGL Stock Ratings
| Growth Rating | -84.4% |
| Fundamental | 37.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -79.0% |
| Analyst Rating | 3.30 of 5 |
AGL Dividends
Currently no dividends paidAGL Growth Ratios
| Growth Correlation 3m | -79.9% |
| Growth Correlation 12m | -56.4% |
| Growth Correlation 5y | -92.7% |
| CAGR 5y | -67.58% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.69 |
| CAGR/Mean DD 3y (Pain Ratio) | -1.06 |
| Sharpe Ratio 12m | -0.59 |
| Alpha | -80.80 |
| Beta | 0.077 |
| Volatility | 97.29% |
| Current Volume | 10059.4k |
| Average Volume 20d | 7118.6k |
| Stop Loss | 0.6 (-10.4%) |
| Signal | -1.43 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-315.7m TTM) > 0 and > 6% of Revenue (6% = 354.1m TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA 4.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.45% (prev 9.27%; Δ -5.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.03 (>3.0%) and CFO -58.4m > Net Income -315.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (413.8m) change vs 12m ago 0.62% (target <= -2.0% for YES) |
| Gross Margin -1.87% (prev 0.49%; Δ -2.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 304.5% (prev 247.7%; Δ 56.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -51.67 (EBITDA TTM -297.8m / Interest Expense TTM 6.28m) >= 6 (WARN >= 3) |
Altman Z'' -4.89
| (A) 0.12 = (Total Current Assets 1.45b - Total Current Liabilities 1.25b) / Total Assets 1.71b |
| (B) -0.98 = Retained Earnings (Balance) -1.68b / Total Assets 1.71b |
| (C) -0.17 = EBIT TTM -324.7m / Avg Total Assets 1.94b |
| (D) -1.28 = Book Value of Equity -1.67b / Total Liabilities 1.30b |
| Total Rating: -4.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.97
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -35.27% = -5.0 |
| 3. FCF Margin -1.20% = -0.45 |
| 4. Debt/Equity 0.10 = 2.49 |
| 5. Debt/Ebitda 0.44 = 2.35 |
| 6. ROIC - WACC (= -68.06)% = -12.50 |
| 7. RoE -64.59% = -2.50 |
| 8. Rev. Trend 82.70% = 6.20 |
| 9. EPS Trend -12.57% = -0.63 |
What is the price of AGL shares?
Over the past week, the price has changed by -16.23%, over one month by -37.06%, over three months by -23.75% and over the past year by -76.09%.
Is agilon health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AGL is around 0.28 USD . This means that AGL is currently overvalued and has a potential downside of -58.21%.
Is AGL a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 14
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the AGL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.2 | 83.6% |
| Analysts Target Price | 1.2 | 83.6% |
| ValueRay Target Price | 0.3 | -53.7% |
AGL Fundamental Data Overview November 02, 2025
P/E Forward = 178.5714
P/S = 0.0559
P/B = 1.0945
Beta = 0.077
Revenue TTM = 5.90b USD
EBIT TTM = -324.7m USD
EBITDA TTM = -297.8m USD
Long Term Debt = 34.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 34.9m USD (from shortTermDebt, last quarter)
Debt = 41.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -130.0m USD (from netDebt column, last quarter)
Enterprise Value = 200.0m USD (330.1m + Debt 41.4m - CCE 171.4m)
Interest Coverage Ratio = -51.67 (Ebit TTM -324.7m / Interest Expense TTM 6.28m)
FCF Yield = -35.27% (FCF TTM -70.6m / Enterprise Value 200.0m)
FCF Margin = -1.20% (FCF TTM -70.6m / Revenue TTM 5.90b)
Net Margin = -5.35% (Net Income TTM -315.7m / Revenue TTM 5.90b)
Gross Margin = -1.87% ((Revenue TTM 5.90b - Cost of Revenue TTM 6.01b) / Revenue TTM)
Gross Margin QoQ = -3.76% (prev 3.31%)
Tobins Q-Ratio = 0.12 (Enterprise Value 200.0m / Total Assets 1.71b)
Interest Expense / Debt = 3.80% (Interest Expense 1.57m / Debt 41.4m)
Taxrate = -0.06% (negative due to tax credits) (62.0k / -104.3m)
NOPAT = -324.9m (EBIT -324.7m * (1 - -0.06%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.16 (Total Current Assets 1.45b / Total Current Liabilities 1.25b)
Debt / Equity = 0.10 (Debt 41.4m / totalStockholderEquity, last quarter 408.9m)
Debt / EBITDA = 0.44 (negative EBITDA) (Net Debt -130.0m / EBITDA -297.8m)
Debt / FCF = 1.84 (negative FCF - burning cash) (Net Debt -130.0m / FCF TTM -70.6m)
Total Stockholder Equity = 488.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.43% (Net Income -315.7m / Total Assets 1.71b)
RoE = -64.59% (Net Income TTM -315.7m / Total Stockholder Equity 488.8m)
RoCE = -62.00% (EBIT -324.7m / Capital Employed (Equity 488.8m + L.T.Debt 34.9m))
RoIC = -62.03% (negative operating profit) (NOPAT -324.9m / Invested Capital 523.7m)
WACC = 6.02% (E(330.1m)/V(371.5m) * Re(6.30%) + D(41.4m)/V(371.5m) * Rd(3.80%) * (1-Tc(-0.00)))
Discount Rate = 6.30% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.37%
Fair Price DCF = unknown (Cash Flow -70.6m)
EPS Correlation: -12.57 | EPS CAGR: 16.01% | SUE: 2.05 | # QB: 1
Revenue Correlation: 82.70 | Revenue CAGR: 28.84% | SUE: -0.99 | # QB: 0
Additional Sources for AGL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle